WO2003074567A3 - Internalizing anti-cd74 antibodies and methods of use - Google Patents

Internalizing anti-cd74 antibodies and methods of use Download PDF

Info

Publication number
WO2003074567A3
WO2003074567A3 PCT/GB2003/000890 GB0300890W WO03074567A3 WO 2003074567 A3 WO2003074567 A3 WO 2003074567A3 GB 0300890 W GB0300890 W GB 0300890W WO 03074567 A3 WO03074567 A3 WO 03074567A3
Authority
WO
WIPO (PCT)
Prior art keywords
antibodies
methods
diagnosis
treatment
malignancies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB2003/000890
Other languages
French (fr)
Other versions
WO2003074567A2 (en
Inventor
Hans Hansen
Shui-On Leung
Zhengxing Qu
David M Goldenberg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immunomedics Inc
Original Assignee
Immunomedics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27788972&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2003074567(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to KR1020047013665A priority Critical patent/KR101017732B1/en
Priority to EP03743421.4A priority patent/EP1483294B2/en
Priority to CA2478012A priority patent/CA2478012C/en
Priority to CN038098636A priority patent/CN1649902B/en
Priority to ES03743421T priority patent/ES2350477T5/en
Priority to AU2003215732A priority patent/AU2003215732B2/en
Priority to IL16385103A priority patent/IL163851A0/en
Application filed by Immunomedics Inc filed Critical Immunomedics Inc
Priority to HK05104748.2A priority patent/HK1071576B/en
Priority to JP2003573032A priority patent/JP4472351B2/en
Priority to DE60333732T priority patent/DE60333732D1/en
Priority to DK03743421.4T priority patent/DK1483294T3/en
Priority to AT03743421T priority patent/ATE477276T1/en
Publication of WO2003074567A2 publication Critical patent/WO2003074567A2/en
Publication of WO2003074567A3 publication Critical patent/WO2003074567A3/en
Priority to IL163851A priority patent/IL163851A/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Neurology (AREA)
  • Optics & Photonics (AREA)
  • Obesity (AREA)
  • Food Science & Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Transplantation (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)

Abstract

The present invention provides humanized, chimeric and human anti-CD74 antibodies, CD74 antibody fusion proteins, immunoconjugates, vaccines and bispecific that bind to CD74, the major histocompatibility complex (MHC) class-II invariant chain, Ii, which is useful for the treatment and diagnosis of B-cell disorders, such as B-cell malignancies, other malignancies in which the cells are reactive with CD74, and autoimmune diseases, and methods of treatment and diagnosis.
PCT/GB2003/000890 2002-03-01 2003-03-03 Internalizing anti-cd74 antibodies and methods of use Ceased WO2003074567A2 (en)

Priority Applications (13)

Application Number Priority Date Filing Date Title
AT03743421T ATE477276T1 (en) 2002-03-01 2003-03-03 INTERNALIZATION OF ANTI CD74 MONOCLONAL ANTIBODIES AND THEIR USES
HK05104748.2A HK1071576B (en) 2002-03-01 2003-03-03 Internalizing anti-cd74 antibodies and methods of use
CA2478012A CA2478012C (en) 2002-03-01 2003-03-03 Internalizing anti-cd74 antibodies and methods of use
CN038098636A CN1649902B (en) 2002-03-01 2003-03-03 Internalizing Anti-CD74 Antibodies and Methods of Use
ES03743421T ES2350477T5 (en) 2002-03-01 2003-03-03 Internalization of anti-CD74 antibodies and methods of use
AU2003215732A AU2003215732B2 (en) 2002-03-01 2003-03-03 Internalizing anti-CD74 antibodies and methods of use
IL16385103A IL163851A0 (en) 2002-03-01 2003-03-03 Internalizing anti-cd74 antibodies and methods of use
KR1020047013665A KR101017732B1 (en) 2002-03-01 2003-03-03 Internalized anti-CD74 antibodies and methods of using the same
JP2003573032A JP4472351B2 (en) 2002-03-01 2003-03-03 Internalizing anti-CD74 antibody and method of use thereof
DE60333732T DE60333732D1 (en) 2002-03-01 2003-03-03 INTERNALIZATION OF ANTI CD74 MONOCLONAL ANTIBODIES AND THEIR USES
EP03743421.4A EP1483294B2 (en) 2002-03-01 2003-03-03 Internalizing anti-cd74 antibodies and methods of use
DK03743421.4T DK1483294T3 (en) 2002-03-01 2003-03-03 Internalizing anti-CD74 antibodies and methods for their use
IL163851A IL163851A (en) 2002-03-01 2004-08-31 Internalizing anti-cd74 antibodies and methods of use

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36025902P 2002-03-01 2002-03-01
US60/360,259 2002-03-01

Publications (2)

Publication Number Publication Date
WO2003074567A2 WO2003074567A2 (en) 2003-09-12
WO2003074567A3 true WO2003074567A3 (en) 2003-12-31

Family

ID=27788972

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2003/000890 Ceased WO2003074567A2 (en) 2002-03-01 2003-03-03 Internalizing anti-cd74 antibodies and methods of use

Country Status (13)

Country Link
US (8) US7312318B2 (en)
EP (3) EP2865688A1 (en)
JP (2) JP4472351B2 (en)
KR (1) KR101017732B1 (en)
CN (2) CN102174108B (en)
AT (1) ATE477276T1 (en)
AU (2) AU2003215732B2 (en)
CA (1) CA2478012C (en)
DE (1) DE60333732D1 (en)
DK (1) DK1483294T3 (en)
ES (1) ES2350477T5 (en)
IL (2) IL163851A0 (en)
WO (1) WO2003074567A2 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8906378B2 (en) 2005-04-06 2014-12-09 Ibc Pharmaceuticals, Inc. Combination therapy with anti-CD74 antibodies provides enhanced toxicity to malignancies, autoimmune disease and other diseases
US10981987B2 (en) 2007-07-16 2021-04-20 Genentech, Inc. Humanized anti-CD79b antibodies and immunoconjugates and methods of use
US11000510B2 (en) 2014-09-23 2021-05-11 Genentech, Inc. Methods of using anti-CD79b immunoconjugates

Families Citing this family (182)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0757213A (en) * 1993-08-13 1995-03-03 Matsushita Electric Ind Co Ltd Magnetic head
US6183744B1 (en) * 1997-03-24 2001-02-06 Immunomedics, Inc. Immunotherapy of B-cell malignancies using anti-CD22 antibodies
US8383081B2 (en) 1999-05-10 2013-02-26 Immunomedics, Inc. Anti-CD74 immunoconjugates and methods of use
US7829064B2 (en) * 1999-05-10 2010-11-09 Immunomedics, Inc. Anti-CD74 immunoconjugates and methods
EP1194167B1 (en) * 1999-06-09 2009-08-19 Immunomedics, Inc. Immunotherapy of autoimmune disorders using antibodies which target b-cells
US20110045005A1 (en) 2001-10-19 2011-02-24 Craig Crowley Compositions and methods for the treatment of tumor of hematopoietic origin
US7591994B2 (en) * 2002-12-13 2009-09-22 Immunomedics, Inc. Camptothecin-binding moiety conjugates
US8435529B2 (en) 2002-06-14 2013-05-07 Immunomedics, Inc. Combining radioimmunotherapy and antibody-drug conjugates for improved cancer therapy
US20160279239A1 (en) * 2011-05-02 2016-09-29 Immunomedics, Inc. Subcutaneous administration of anti-cd74 antibody for systemic lupus erythematosus and autoimmune disease
US9770517B2 (en) 2002-03-01 2017-09-26 Immunomedics, Inc. Anti-Trop-2 antibody-drug conjugates and uses thereof
US8361464B2 (en) 2002-03-01 2013-01-29 Immunomedics, Inc. Anthracycline-Antibody Conjugates for Cancer Therapy
JP4472351B2 (en) * 2002-03-01 2010-06-02 イミューノメディクス、インコーポレイテッド Internalizing anti-CD74 antibody and method of use thereof
US7906118B2 (en) 2005-04-06 2011-03-15 Ibc Pharmaceuticals, Inc. Modular method to prepare tetrameric cytokines with improved pharmacokinetics by the dock-and-lock (DNL) technology
US8871446B2 (en) 2002-10-02 2014-10-28 California Institute Of Technology Microfluidic nucleic acid analysis
US8420086B2 (en) 2002-12-13 2013-04-16 Immunomedics, Inc. Camptothecin conjugates of anti-CD22 antibodies for treatment of B cell diseases
JP4959136B2 (en) 2002-12-13 2012-06-20 イミューノメディクス、インコーポレイテッド Immunoconjugates with cleavable linkages in cells
US7534427B2 (en) * 2002-12-31 2009-05-19 Immunomedics, Inc. Immunotherapy of B cell malignancies and autoimmune diseases using unconjugated antibodies and conjugated antibodies and antibody combinations and fusion proteins
US20040202666A1 (en) * 2003-01-24 2004-10-14 Immunomedics, Inc. Anti-cancer anthracycline drug-antibody conjugates
JP4874090B2 (en) * 2003-01-31 2012-02-08 イミューノメディクス、インコーポレイテッド Methods and compositions for administering therapeutic and diagnostic agents
KR100930353B1 (en) 2003-03-06 2009-12-08 엘지전자 주식회사 How to handle connection request of disc player
US7902338B2 (en) 2003-07-31 2011-03-08 Immunomedics, Inc. Anti-CD19 antibodies
US20050079184A1 (en) * 2003-08-08 2005-04-14 Immunomedics, Inc. Bispecific antibodies for inducing apoptosis of tumor and diseased cells
US20060228331A1 (en) 2003-10-10 2006-10-12 Novo Nordisk A/S IL-21 Derivatives and variants
MXPA06004199A (en) * 2003-10-17 2006-06-28 Novo Nordisk As Combination therapy.
PL2295073T3 (en) * 2003-11-17 2014-09-30 Genentech Inc Antibody against CD22 for the treatment of tumour of hematopoietic origin
US20110064754A1 (en) * 2005-03-03 2011-03-17 Center For Molecular Medicine And Immunology Immunoconjugates Comprising Poxvirus-Derived Peptides and Antibodies Against Antigen-Presenting Cells for Subunit-Based Poxvirus Vaccines
US9481878B2 (en) 2004-02-13 2016-11-01 Immunomedics, Inc. Compositions and methods of use of immunotoxins comprising ranpirnase (Rap) show potent cytotoxic activity
US8435539B2 (en) * 2004-02-13 2013-05-07 Immunomedics, Inc. Delivery system for cytotoxic drugs by bispecific antibody pretargeting
US8562988B2 (en) * 2005-10-19 2013-10-22 Ibc Pharmaceuticals, Inc. Strategies for improved cancer vaccines
US9550838B2 (en) 2004-02-13 2017-01-24 Ibc Pharmaceuticals, Inc. Dock-and-lock (DNL) complexes for therapeutic and diagnostic use
US8652484B2 (en) 2004-02-13 2014-02-18 Immunomedics, Inc. Delivery system for cytotoxic drugs by bispecific antibody pretargeting
US8883160B2 (en) * 2004-02-13 2014-11-11 Ibc Pharmaceuticals, Inc. Dock-and-lock (DNL) complexes for therapeutic and diagnostic use
US8551480B2 (en) 2004-02-13 2013-10-08 Immunomedics, Inc. Compositions and methods of use of immunotoxins comprising ranpirnase (Rap) show potent cytotoxic activity
US20110020273A1 (en) * 2005-04-06 2011-01-27 Ibc Pharmaceuticals, Inc. Bispecific Immunocytokine Dock-and-Lock (DNL) Complexes and Therapeutic Use Thereof
US8491914B2 (en) * 2004-02-13 2013-07-23 Ibc Pharmaceuticals, Inc. Dock-and-lock (DNL) complexes for delivery of interference RNA
US7589063B2 (en) 2004-12-14 2009-09-15 Aplagen Gmbh Molecules which promote hematopoiesis
US10058621B2 (en) 2015-06-25 2018-08-28 Immunomedics, Inc. Combination therapy with anti-HLA-DR antibodies and kinase inhibitors in hematopoietic cancers
US9707302B2 (en) 2013-07-23 2017-07-18 Immunomedics, Inc. Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
ES2829566T3 (en) 2005-03-03 2021-06-01 Immunomedics Inc Humanized L243 Antibodies
US20160355591A1 (en) 2011-05-02 2016-12-08 Immunomedics, Inc. Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies
JP2006248978A (en) * 2005-03-10 2006-09-21 Mebiopharm Co Ltd New liposome preparation
US8349332B2 (en) 2005-04-06 2013-01-08 Ibc Pharmaceuticals, Inc. Multiple signaling pathways induced by hexavalent, monospecific and bispecific antibodies for enhanced toxicity to B-cell lymphomas and other diseases
ES2417065T3 (en) 2005-04-26 2013-08-05 Trion Pharma Gmbh Combination of antibodies with glucocorticoids for cancer treatment
BRPI0611069A2 (en) * 2005-05-06 2010-11-09 Zymogenetics Inc monoclonal antibody, humanized antibody, antibody fragment, use of an antagonist, and hybridoma
US20090281278A1 (en) * 2006-03-09 2009-11-12 Hans-Georg Frank Modified molecules which promote hematopoiesis
WO2007140371A2 (en) 2006-05-30 2007-12-06 Genentech, Inc. Antibodies and immunoconjugates and uses therefor
EP2097097B1 (en) 2006-12-01 2018-05-30 E. R. Squibb & Sons, L.L.C. Antibodies, in particular human antibodies, that bind cd22 and uses thereof
US8557764B2 (en) * 2007-01-26 2013-10-15 The Regents Of The University Of Colorado, A Body Corporate Methods of modulating immune function
ATE543835T1 (en) 2007-07-16 2012-02-15 Genentech Inc ANTI-CD79B ANTIBODIES AND IMMUNE CONJUGATES AND METHODS OF APPLICATION
AU2008317374B2 (en) 2007-10-23 2015-03-19 The Regents Of The University Of Colorado Competitive inhibitors of invariant chain expression and/or ectopic clip binding
CN101959429B (en) 2008-01-08 2014-09-10 阿克塞利亚制药公司 Agonists of the antimicrobial peptide system
PT2242512T (en) 2008-01-15 2016-07-18 Univ Leland Stanford Junior METHODS FOR MANIPULATING FAGOCYTOSIS MEDIATED BY CD47
US11072655B2 (en) 2008-01-15 2021-07-27 The Board Of Trustees Of The Leland Stanford Junior University Markers of acute myeloid leukemia stem cells
CA3108119C (en) 2008-01-15 2024-01-16 The Board Of Trustees Of The Leland Stanford Junior University Markers of acute myeloid leukemia stem cells
PT2247620T (en) 2008-01-31 2016-08-23 Genentech Inc ANTIBODIES AND IMMUNOCONJUGATES ANTI-CD79B AND METHODS OF USE
WO2009117710A2 (en) * 2008-03-20 2009-09-24 Carolus Therapeutics, Inc. Methods of treating inflammation
US20110070184A1 (en) * 2008-03-24 2011-03-24 Carolus Therpeutics, Inc. Methods and compositions for treating atherosclerosis and related condidtions
CN102186499B (en) * 2008-08-20 2015-05-20 Ibc医药公司 Dock and Lock (DNL) Vaccines for Cancer Therapy
WO2010056910A2 (en) * 2008-11-12 2010-05-20 Carolus Therapeutics, Inc. Methods of treating cardiovascular disorders
EP4209510B1 (en) 2008-12-09 2024-01-31 F. Hoffmann-La Roche AG Anti-pd-l1 antibodies and their use to enhance t-cell function
EP2198879A1 (en) * 2008-12-11 2010-06-23 Institut Curie CD74 modulator agent for regulating dendritic cell migration and device for studying the motility capacity of a cell
EP3243527B1 (en) 2009-02-13 2019-06-05 Immunomedics, Inc. Immunoconjugates with an intracellularly-cleavable linkage
CA2774260C (en) 2009-09-16 2018-10-09 Immunomedics, Inc. Class i anti-cea antibodies and uses thereof
WO2011038149A2 (en) * 2009-09-23 2011-03-31 Carolus Therapeutics, Inc. Methods of treating inflammation
AU2010315432A1 (en) * 2009-11-05 2012-04-12 Center For Molecular Medicine And Immunology Immunoconjugates comprising poxvirus-derived peptides and antibodies against antigen-presenting cells for subunit-based poxvirus vaccines
EP2506881B1 (en) 2009-12-02 2024-03-06 Immunomedics, Inc. Combining radioimmunotherapy and antibody-drug conjugates for improved cancer therapy
WO2011085354A1 (en) * 2010-01-11 2011-07-14 Center For Molecular Medicine And Immunology Enhanced cytotoxicity of anti-cd74 and anti-hla-dr antibodies with interferon-gamma
CA2794499A1 (en) * 2010-04-01 2011-10-06 Immumomedics, Inc. Antibody-based depletion of antigen-presenting cells and dendritic cells
DE102010026063A1 (en) * 2010-06-30 2012-01-05 Siemens Aktiengesellschaft 11C-labeled peptide for the detection of a diseased tissue
DE102010026064A1 (en) * 2010-06-30 2012-01-05 Siemens Aktiengesellschaft 11C-labeled peptide for the detection of a diseased tissue
EP2605788B1 (en) * 2010-08-17 2018-10-10 IBC Pharmaceuticals, Inc. Combination therapy with anti-cd74 antibodies provides enhanced toxicity to malignancies, autoimmune disease and other diseases
WO2012031273A2 (en) 2010-09-03 2012-03-08 Stem Centrx, Inc. Novel modulators and methods of use
CA2860768A1 (en) 2011-01-05 2013-07-12 The Texas A&M University System Clip modulation for the treatment of mucosal diseases
EP2670440B1 (en) * 2011-02-01 2018-09-05 Genmab A/S Human antibodies and antibody-drug conjugates against cd74
US8673308B2 (en) * 2011-02-23 2014-03-18 Als Therapy Development Institute Targeting of CD8+ T-lymphocytes to treat neurodegenerative diseases
AU2012250924B2 (en) 2011-05-02 2017-05-25 Immunomedics, Inc. Ultrafiltration concentration of allotype selected antibodies for small-volume administration
EP2734228A4 (en) 2011-07-18 2015-04-08 Ohio State Innovation Foundation Fty720 increases cd74 expression and sensitizes cancer cells to anti-cd74 antibody-mediated cell death
AU2012328819B2 (en) 2011-10-26 2017-08-03 Elanco Tiergesundheit Ag Monoclonal antibodies and methods of use
WO2013059885A2 (en) 2011-10-28 2013-05-02 Cephalon Australia Pty Ltd Polypeptide constructs and uses thereof
EP2788020A4 (en) 2011-12-05 2015-04-29 Immunomedics Inc Therapeutic use of anti-cd22 antibodies for inducing trogocytosis
US9757458B2 (en) 2011-12-05 2017-09-12 Immunomedics, Inc. Crosslinking of CD22 by epratuzumab triggers BCR signaling and caspase-dependent apoptosis in hematopoietic cancer cells
AU2013263076B2 (en) 2012-05-15 2017-08-31 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
AU2013274078A1 (en) 2012-06-14 2015-01-29 Ambrx, Inc. Anti-PSMA antibodies conjugated to nuclear receptor ligand polypeptides
US20150231241A1 (en) 2012-08-14 2015-08-20 Ibc Pharmaceuticals, Inc. Combination therapy for inducing immune response to disease
US9682143B2 (en) 2012-08-14 2017-06-20 Ibc Pharmaceuticals, Inc. Combination therapy for inducing immune response to disease
US9382329B2 (en) 2012-08-14 2016-07-05 Ibc Pharmaceuticals, Inc. Disease therapy by inducing immune response to Trop-2 expressing cells
WO2014028560A2 (en) 2012-08-14 2014-02-20 Ibc Pharmaceuticals, Inc. T-cell redirecting bispecific antibodies for treatment of disease
GB201216649D0 (en) * 2012-09-18 2012-10-31 Univ Birmingham Agents and methods
EP2905290B1 (en) 2012-10-05 2019-12-04 Kyowa Kirin Co., Ltd. Heterodimeric protein composition
ES2738310T3 (en) 2012-10-12 2020-01-21 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
US20240148873A1 (en) 2012-12-13 2024-05-09 Immunomedics, Inc. Dosages of immunoconjugates of antibodies and sn-38 for improved efficacy and decreased toxicity
US9107960B2 (en) 2012-12-13 2015-08-18 Immunimedics, Inc. Antibody-SN-38 immunoconjugates with a CL2A linker
WO2017004144A1 (en) 2015-07-01 2017-01-05 Immunomedics, Inc. Antibody-sn-38 immunoconjugates with a cl2a linker
US10206918B2 (en) 2012-12-13 2019-02-19 Immunomedics, Inc. Efficacy of anti-HLA-DR antiboddy drug conjugate IMMU-140 (hL243-CL2A-SN-38) in HLA-DR positive cancers
US10744129B2 (en) 2012-12-13 2020-08-18 Immunomedics, Inc. Therapy of small-cell lung cancer (SCLC) with a topoisomerase-I inhibiting antibody-drug conjugate (ADC) targeting Trop-2
US12310958B2 (en) 2012-12-13 2025-05-27 Immunomedics, Inc. Antibody-drug conjugates and uses thereof
US10137196B2 (en) 2012-12-13 2018-11-27 Immunomedics, Inc. Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity
US10413539B2 (en) 2012-12-13 2019-09-17 Immunomedics, Inc. Therapy for metastatic urothelial cancer with the antibody-drug conjugate, sacituzumab govitecan (IMMU-132)
US9492566B2 (en) 2012-12-13 2016-11-15 Immunomedics, Inc. Antibody-drug conjugates and uses thereof
US9931417B2 (en) 2012-12-13 2018-04-03 Immunomedics, Inc. Antibody-SN-38 immunoconjugates with a CL2A linker
AU2013360335B2 (en) 2012-12-13 2017-12-07 Immunomedics, Inc. Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity
JP2016513098A (en) 2013-02-07 2016-05-12 イミューノメディクス、インコーポレイテッドＩｍｍｕｎｏｍｅｄｉｃｓ， Ｉｎｃ． An extremely potent prodrug form of 2-pyrrolinodoxorubicin (P2PDOX) conjugated with an antibody for cancer targeted therapy
CN104994875B (en) 2013-02-15 2018-10-09 免疫医疗公司 Chimeric and humanization histonic antibody
EP2774930A1 (en) 2013-03-07 2014-09-10 Aptenia S.R.L. Metallocene compounds and labeled molecules comprising the same for in vivo imaging.
JP6815196B2 (en) 2013-03-13 2021-01-20 イマジナブ、 インコーポレイテッド Antigen-binding construct for CD8
CA2905181C (en) 2013-03-13 2020-06-02 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof for providing targeted therapy
CN103207277B (en) * 2013-03-28 2015-04-15 中国人民解放军第二军医大学 ELISA test kit of human-derived soluble CD74 protein and detection method thereof
CA2909952C (en) 2013-04-29 2021-10-12 Teva Pharmaceuticals Australia Pty Ltd. Anti-cd38 antibodies and fusions to attenuated interferon alpha-2b
US11117975B2 (en) 2013-04-29 2021-09-14 Teva Pharmaceuticals Australia Pty Ltd Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B
US11253606B2 (en) 2013-07-23 2022-02-22 Immunomedics, Inc. Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, Bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
WO2015067277A1 (en) 2013-11-07 2015-05-14 University Of Copenhagen Timp-1 binding partner
PT3088419T (en) * 2013-12-25 2019-01-11 Daiichi Sankyo Co Ltd ANTI-TROP2-PHARMACEUTICAL ANTIBODY CONJUGATE
IL285403B2 (en) 2014-01-27 2023-10-01 Molecular Templates Inc Mhc class i epitope delivering polypeptides
JP6447933B2 (en) 2014-02-21 2019-01-09 アイビーシー ファーマスーティカルズ，インコーポレイテッド Disease treatment by inducing an immune response against Trop-2 expressing cells
CA2935748A1 (en) 2014-02-25 2015-09-03 Immunomedics, Inc. Humanized rfb4 anti-cd22 antibody
SI3604333T1 (en) * 2014-03-11 2021-08-31 Molecular Templates, Inc. Proteins comprising aminoterminal proximal Shiga toxin subunit A effector regions and cell-targeting immunoglobulin-type binding regions capable of specific CD38 binding
IL292311A (en) 2014-04-03 2022-06-01 Igm Biosciences Inc Modified j-chain
UA119352C2 (en) 2014-05-01 2019-06-10 Тева Фармасьютикалз Острейліа Пті Лтд COMBINATION OF LENALIDOMIDE OR POMALIDOMIDE AND STRUCTURES OF ANTI-CD38 ANTIBODY-ATHENED INTERPHERONE ALPHA-2B AND METHOD OF TREATMENT38
US10351621B2 (en) 2014-06-24 2019-07-16 Immunomedics, Inc. Anti-histone therapy in acute kidney injury
EP3160504B1 (en) 2014-06-24 2020-09-16 Immunomedics, Inc. Anti-histone therapy for vascular necrosis in severe glomerulonephritis
WO2016037985A1 (en) 2014-09-08 2016-03-17 Ruprecht-Karls-Universität Heidelberg Construct for the delivery of a molecule into the cytoplasm of a cell
US10188746B2 (en) 2014-09-10 2019-01-29 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
CN104280553B (en) * 2014-09-22 2016-06-08 中国人民解放军第二军医大学 The ELISA detection kit of a kind of little mouse soluble type CD74 albumen and detection method
SI3204018T1 (en) 2014-10-07 2021-11-30 Immunomedics, Inc. Neoadjuvant use of antibody-drug conjugates
UA125637C2 (en) 2014-10-29 2022-05-11 Тева Фармасьютікалз Острейліа Пті Лтд MERGER INTERFERON POLYPEPTIDE <font face = "Symbol"> a2 </font> b
US11318163B2 (en) 2015-02-18 2022-05-03 Enlivex Therapeutics Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11304976B2 (en) 2015-02-18 2022-04-19 Enlivex Therapeutics Ltd Combination immune therapy and cytokine control therapy for cancer treatment
CN107530376A (en) 2015-02-18 2018-01-02 恩立夫克治疗有限责任公司 Combined immunization therapy and cell factor control therapy for treatment of cancer
US11497767B2 (en) 2015-02-18 2022-11-15 Enlivex Therapeutics R&D Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11596652B2 (en) 2015-02-18 2023-03-07 Enlivex Therapeutics R&D Ltd Early apoptotic cells for use in treating sepsis
US11000548B2 (en) 2015-02-18 2021-05-11 Enlivex Therapeutics Ltd Combination immune therapy and cytokine control therapy for cancer treatment
MY187178A (en) * 2015-02-18 2021-09-08 Hoffmann La Roche Immunoconjugates for specific induction of t cell cytotoxicity against a target cell
SG11201707144VA (en) 2015-03-04 2017-09-28 Igm Biosciences Inc Cd20 binding molecules and uses thereof
IL287500B2 (en) 2015-04-21 2023-12-01 Enlivex Therapeutics Rdo Ltd Therapeutic preparations from pooled apoptotic blood cells and their use
US9797907B2 (en) 2015-04-22 2017-10-24 Immunomedics, Inc. Isolation, detection, diagnosis and/or characterization of circulating Trop-2-positive cancer cells
HUE051246T2 (en) 2015-05-30 2021-03-01 Molecular Templates Inc Deimmunized shigatoxin subunit scaffolds and cell-targeting molecules containing them
US10195175B2 (en) 2015-06-25 2019-02-05 Immunomedics, Inc. Synergistic effect of anti-Trop-2 antibody-drug conjugate in combination therapy for triple-negative breast cancer when used with microtubule inhibitors or PARP inhibitors
AU2016281622C1 (en) 2015-06-25 2021-11-18 Immunomedics, Inc. Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, Bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
GB201511191D0 (en) * 2015-06-25 2015-08-12 Immatics Biotechnologies Gmbh T-cell epitopes for the immunotherapy of myeloma
KR20250008141A (en) 2015-08-07 2025-01-14 이미지냅 인코포레이티드 Antigen binding constructs to target molecules
CA2999284C (en) 2015-09-30 2023-06-13 Igm Biosciences A/S Binding molecules with modified j-chain
US11639389B2 (en) 2015-09-30 2023-05-02 Igm Biosciences, Inc. Binding molecules with modified J-chain
EP3359194A4 (en) 2015-10-06 2019-04-24 Merck Sharp & Dohme Corp. ANTIBODY-MEDICINAL CONJUGATE FOR ANTI-INFLAMMATORY APPLICATIONS
CA3008102A1 (en) * 2015-12-18 2017-06-22 Novartis Ag Antibodies targeting cd32b and methods of use thereof
EP3407916B1 (en) 2016-01-29 2023-12-20 Merck Sharp & Dohme LLC Phosphonate linkers and their use to facilitate cellular retention of compounds
WO2017139623A1 (en) 2016-02-10 2017-08-17 Immunomedics, Inc. Combination of abcg2 inhibitors with sacituzumab govitecan (immu-132) overcomes resistance to sn-38 in trop-2 expressing cancers
CA3014885A1 (en) 2016-02-18 2017-08-24 Enlivex Therapeutics Ltd. Combination immune therapy and cytokine control therapy for cancer treatment
EP3448260A4 (en) 2016-04-27 2019-10-09 Immunomedics, Inc. EFFICACY OF ANTI-TROP-2-SN-38 MEDICINAL-ANTIBODY CONJUGATES FOR THE TREATMENT OF RECYCLANT / REFRACTORY TUMORS TO CONTROL POINT INHIBITORS
CA3032418C (en) 2016-08-01 2024-02-20 Health Research, Inc. Compositions and methods for rapid cloning of t-cell receptors
WO2018069289A1 (en) 2016-10-11 2018-04-19 Medimmune Limited Antibody-drug conjugates with immune-mediated therapy agents
JP7075134B2 (en) 2016-12-07 2022-05-25 モレキュラー テンプレーツ，インク． Shiga toxin A subunit effector polypeptide for site-specific conjugation, Shiga toxin effector scaffold, and cell targeting molecule
JP7082424B2 (en) 2017-01-25 2022-06-08 モレキュラー テンプレーツ，インク． Cell-targeted molecule containing deimmunized Shiga toxin A subunit effector and CD8 + T cell epitope
US10918734B2 (en) 2017-03-27 2021-02-16 Immunomedics, Inc. Treatment of high Trop-2 expressing triple negative breast cancer (TNBC) with sacituzumab govitecan (IMMU-132) overcomes homologous recombination repair (HRR) rescue mediated by Rad51
CN110352201A (en) 2017-04-03 2019-10-18 免疫医疗公司 The subcutaneous administration of antibody drug conjugate for cancer therapy
CN110662762A (en) * 2017-05-24 2020-01-07 诺华股份有限公司 Antibody cytokine graft proteins and methods for treating cancer
SG11202010469QA (en) 2018-05-23 2020-11-27 Adc Therapeutics Sa Molecular adjuvant
US12594345B2 (en) 2018-09-26 2026-04-07 Ascendis Pharma A/S Degradable hyaluronic acid hydrogels
CN111303293B (en) * 2018-11-14 2022-08-30 杭州尚健生物技术有限公司 Fusion protein and application thereof
CA3138058A1 (en) 2019-05-20 2020-11-26 Matthew T. Burger Mcl-1 inhibitor antibody-drug conjugates and methods of use
US20220411489A1 (en) 2019-11-15 2022-12-29 Attralus, Inc. Modified immunoglobulins for targeting amyloid deposits
AU2021222990A1 (en) * 2020-02-20 2022-09-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Method for identifying functional disease-specific regulatory T cells
US20230256114A1 (en) 2020-07-07 2023-08-17 Bionecure Therapeutics, Inc. Novel maytansinoids as adc payloads and their use for the treatment of cancer
CN115803010A (en) 2020-07-09 2023-03-14 豪夫迈·罗氏有限公司 Concentrated protein compositions, their preparation and use
CN116368154A (en) 2020-10-08 2023-06-30 阿菲姆德股份有限公司 trispecific binder
US20230372528A1 (en) 2020-10-16 2023-11-23 University Of Georgia Research Foundation, Inc. Glycoconjugates
JP2024500847A (en) 2020-12-18 2024-01-10 センチュリー セラピューティクス，インコーポレイテッド Chimeric antigen receptor systems with compatible receptor specificities
GB202102396D0 (en) 2021-02-19 2021-04-07 Adc Therapeutics Sa Molecular adjuvant
EP4342497A1 (en) 2021-05-10 2024-03-27 Kawasaki Institute of Industrial Promotion Antibody having reduced binding affinity for antigen
CN117915949A (en) 2021-05-18 2024-04-19 田纳西大学研究基金会 Antibody-peptide fusion proteins for treating amyloid disorders
CN113238061B (en) * 2021-07-09 2021-10-01 中南大学湘雅医院 Kit and application for indicating the condition of myasthenia gravis by CD180-negative B cells
AU2022320948A1 (en) 2021-07-30 2024-01-18 Affimed Gmbh Duplexbodies
CN118043080A (en) 2021-08-13 2024-05-14 昆山新蕴达生物科技有限公司 An antibody-drug conjugate based on microtubule inhibitors
CN117881431A (en) 2021-08-24 2024-04-12 昆山新蕴达生物科技有限公司 An antibody-drug conjugate coupled by a cleavable linker
EP4408468A4 (en) 2021-09-28 2025-07-02 Frontaim Biomedicines Inc MULTIPLE FORMATS OF MOLECULAR COMPLEXES
JP2024543822A (en) 2021-11-03 2024-11-26 アフィメド ゲーエムベーハー Bispecific CD16A binders
CN117980327A (en) 2021-11-03 2024-05-03 杭州多禧生物科技有限公司 Specific conjugation of antibodies
WO2023103854A1 (en) 2021-12-09 2023-06-15 昆山新蕴达生物科技有限公司 Antibody-drug conjugate having improved affinity, and preparation method therefor and application thereof
PE20251072A1 (en) 2022-05-20 2025-04-10 Novartis Ag Antibody-drug conjugates of antineoplastic compounds and methods of using them
CN119698305A (en) 2022-08-10 2025-03-25 兴和株式会社 New drug complex
CN116139267A (en) * 2023-01-28 2023-05-23 华中科技大学同济医学院附属同济医院 Application of mouse CD74 monoclonal antibody in preparation of tumor treatment drugs
WO2025220804A1 (en) * 2024-04-18 2025-10-23 주식회사 큐로셀 Novel antibody against cd5 and uses thereof
TW202606758A (en) * 2024-05-31 2026-02-16 美商維泰克斯製藥公司 Anti-cd74 antibody compositions and methods

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998050435A1 (en) * 1997-05-02 1998-11-12 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Immunotoxins, comprising an onc protein, directed against malignant cells
WO2000067795A1 (en) * 1999-05-10 2000-11-16 Immunomedics, Inc. Immunotherapy of b-cell malignancies using anti-cd22 antibodies
WO2000074718A1 (en) * 1999-06-09 2000-12-14 Immunomedics, Inc. Immunotherapy of autoimmune disorders using antibodies which target b-cells

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1541435A (en) 1975-02-04 1979-02-28 Searle & Co Immunological materials
US4036945A (en) 1976-05-03 1977-07-19 The Massachusetts General Hospital Composition and method for determining the size and location of myocardial infarcts
US4331647A (en) 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
US5204095A (en) 1980-04-09 1993-04-20 National Research Development Corporation Monoclonal antibodies against hepatitis B virus
US4916213A (en) 1983-02-22 1990-04-10 Xoma Corporation Ribosomal inhibiting protein-immunoglobulin conjugates with specificity for tumor cell surface antigens, and mixtures thereof
US4925922A (en) 1983-02-22 1990-05-15 Xoma Corporation Potentiation of cytotoxic conjugates
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5672347A (en) * 1984-07-05 1997-09-30 Genentech, Inc. Tumor necrosis factor antagonists and their use
US4824659A (en) 1985-06-07 1989-04-25 Immunomedics, Inc. Antibody conjugates
US5776093A (en) 1985-07-05 1998-07-07 Immunomedics, Inc. Method for imaging and treating organs and tissues
US4918163A (en) 1985-09-27 1990-04-17 Pfizer Inc. Monoclonal antibodies specific for lipid-A determinants of gram negative bacteria
US5618920A (en) * 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
US5057313A (en) 1986-02-25 1991-10-15 The Center For Molecular Medicine And Immunology Diagnostic and therapeutic antibody conjugates
US4699784A (en) 1986-02-25 1987-10-13 Center For Molecular Medicine & Immunology Tumoricidal methotrexate-antibody conjugate
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4704692A (en) 1986-09-02 1987-11-03 Ladner Robert C Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
US5258498A (en) * 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
US5846534A (en) * 1988-02-12 1998-12-08 British Technology Group Limited Antibodies to the antigen campath-1
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5134075A (en) 1989-02-17 1992-07-28 Oncogen Limited Partnership Monoclonal antibody to novel antigen associated with human tumors
US5171665A (en) 1989-04-17 1992-12-15 Oncogen Monoclonal antibody to novel antigen associated with human tumors
JPH02283294A (en) 1989-04-24 1990-11-20 Sumitomo Chem Co Ltd Human monoclonal antibody
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5665595A (en) * 1991-06-07 1997-09-09 Dowelanco Immunoglobulins against insect tissue
US5965132A (en) * 1992-03-05 1999-10-12 Board Of Regents, The University Of Texas System Methods and compositions for targeting the vasculature of solid tumors
US5686072A (en) * 1992-06-17 1997-11-11 Board Of Regents, The University Of Texas Epitope-specific monoclonal antibodies and immunotoxins and uses thereof
US5736137A (en) * 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
DE69303494T2 (en) * 1992-11-13 1997-01-16 Idec Pharma Corp THERAPEUTIC USE OF CHIMERIC AND LABELED ANTIBODIES AGAINST HUMAN B LYMPHOCYTIC LIMITED DIFFERENTIATION ANTIQUES FOR THE TREATMENT OF B CELL LYMPHOMA
US6080407A (en) * 1993-05-17 2000-06-27 The Picower Institute For Medical Research Diagnostic assays for MIF
US5484892A (en) * 1993-05-21 1996-01-16 Dana-Farber Cancer Institute, Inc. Monoclonal antibodies that block ligand binding to the CD22 receptor in mature B cells
US6084067A (en) * 1993-07-26 2000-07-04 Dana-Farber Cancer Institute CTLA4/CD28 ligands and uses therefor
US5417972A (en) * 1993-08-02 1995-05-23 The Board Of Trustees Of The Leland Stanford Junior University Method of killing B-cells in a complement independent and an ADCC independent manner using antibodies which specifically bind CDIM
US5443953A (en) 1993-12-08 1995-08-22 Immunomedics, Inc. Preparation and use of immunoconjugates
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
AU3272695A (en) 1994-08-12 1996-03-07 Immunomedics Inc. Immunoconjugates and humanized antibodies specific for b-cell lymphoma and leukemia cells
US5874540A (en) 1994-10-05 1999-02-23 Immunomedics, Inc. CDR-grafted type III anti-CEA humanized mouse monoclonal antibodies
US5728369A (en) * 1994-10-05 1998-03-17 Immunomedics, Inc. Radioactive phosphorus labeling of proteins for targeted radiotherapy
US5798554A (en) 1995-02-24 1998-08-25 Consorzio Per La Ricerca Sulla Microelettronica Nel Mezzogiorno MOS-technology power device integrated structure and manufacturing process thereof
AUPO591797A0 (en) * 1997-03-27 1997-04-24 Commonwealth Scientific And Industrial Research Organisation High avidity polyvalent and polyspecific reagents
ATE267610T1 (en) 1996-03-20 2004-06-15 Immunomedics Inc GLYCOSYLATED IGG ANTIBODIES
ATE365562T1 (en) 1996-05-03 2007-07-15 Immunomedics Inc TARGETED COMBINATION IMMUNOTHERAPY FOR CANCER
US7521531B2 (en) * 1996-08-28 2009-04-21 Immunomedics, Inc. Methods for the purification of stable radioiodine conjugates
US6653104B2 (en) * 1996-10-17 2003-11-25 Immunomedics, Inc. Immunotoxins, comprising an internalizing antibody, directed against malignant and normal cells
US6051228A (en) * 1998-02-19 2000-04-18 Bristol-Myers Squibb Co. Antibodies against human CD40
DE69938054T2 (en) 1998-11-18 2009-02-12 Genentech, Inc., South San Francisco ANTIBODY VARIANTS HAVING HIGHER BINDING SAFFINITIES COMPARED TO PARENTAL ANTIBODIES
CN100457914C (en) 1999-04-15 2009-02-04 荷兰克鲁塞尔公司 Production of Recombinant Proteins in Human Cells Using the Sequence Encoding the E1 Protein of Adenovirus
ATE311199T1 (en) * 1999-05-07 2005-12-15 Genentech Inc TREATMENT OF AUTOIMMUNE DISEASES WITH ANTAGONISTS THAT BIND SURFACE MARKERS OF B CELLS
US7534866B2 (en) * 2005-10-19 2009-05-19 Ibc Pharmaceuticals, Inc. Methods and compositions for generating bioactive assemblies of increased complexity and uses
US7829064B2 (en) * 1999-05-10 2010-11-09 Immunomedics, Inc. Anti-CD74 immunoconjugates and methods
US8383081B2 (en) * 1999-05-10 2013-02-26 Immunomedics, Inc. Anti-CD74 immunoconjugates and methods of use
US7527787B2 (en) * 2005-10-19 2009-05-05 Ibc Pharmaceuticals, Inc. Multivalent immunoglobulin-based bioactive assemblies
CN1981868A (en) * 2000-03-31 2007-06-20 拜奥根Idec公司 Combined use of anti-cytokine antibodies or antagonists and anti-CD20 for treatment of B cell lymphoma
US6629995B1 (en) * 2000-03-31 2003-10-07 Super Gen, Inc. Camptothecin conjugates
AU6836301A (en) * 2000-06-20 2002-01-02 Idec Pharma Corp Treatment of b-cell associated diseases such as malignancies and autoimmune diseases using a cold anti-cd20 antibody/radiolabeled anti-cd22 antibody combination
HUP0303930A3 (en) * 2001-01-26 2012-09-28 Univ Emory Methods of inducing organ transplant tolerance and correcting hemoglobinopathies
EP1383919B1 (en) * 2001-03-29 2010-07-07 Cytokine Pharmasciences, Inc. Methods and compositions for using mhc class ii invariant chain polypeptide as a receptor for macrophage migration inhibitory factor
US8287864B2 (en) * 2002-02-14 2012-10-16 Immunomedics, Inc. Structural variants of antibodies for improved therapeutic characteristics
US7591994B2 (en) * 2002-12-13 2009-09-22 Immunomedics, Inc. Camptothecin-binding moiety conjugates
US8361464B2 (en) * 2002-03-01 2013-01-29 Immunomedics, Inc. Anthracycline-Antibody Conjugates for Cancer Therapy
JP4472351B2 (en) * 2002-03-01 2010-06-02 イミューノメディクス、インコーポレイテッド Internalizing anti-CD74 antibody and method of use thereof
US7563433B2 (en) * 2007-01-11 2009-07-21 Immunomedics, Inc. Methods and compositions for F-18 labeling of proteins, peptides and other molecules
JP4959136B2 (en) * 2002-12-13 2012-06-20 イミューノメディクス、インコーポレイテッド Immunoconjugates with cleavable linkages in cells
JP4874090B2 (en) * 2003-01-31 2012-02-08 イミューノメディクス、インコーポレイテッド Methods and compositions for administering therapeutic and diagnostic agents
CA2604032C (en) * 2005-04-06 2017-08-22 Ibc Pharmaceuticals, Inc. Methods for generating stably linked complexes composed of homodimers, homotetramers or dimers of dimers and uses
US8067006B2 (en) * 2005-04-06 2011-11-29 Immunomedics, Inc. Polymeric carriers of therapeutic agents and recognition moieties for antibody-based targeting of disease sites
CN102186499B (en) * 2008-08-20 2015-05-20 Ibc医药公司 Dock and Lock (DNL) Vaccines for Cancer Therapy
KR102188537B1 (en) 2019-08-14 2020-12-08 라인플러스 주식회사 Method and system for group call using unicast and multicast

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998050435A1 (en) * 1997-05-02 1998-11-12 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Immunotoxins, comprising an onc protein, directed against malignant cells
WO2000067795A1 (en) * 1999-05-10 2000-11-16 Immunomedics, Inc. Immunotherapy of b-cell malignancies using anti-cd22 antibodies
WO2000074718A1 (en) * 1999-06-09 2000-12-14 Immunomedics, Inc. Immunotherapy of autoimmune disorders using antibodies which target b-cells

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BENDIG M M: "HUMANIZATION OF RODENT MONOCLONAL ANTIBODIES BY CDR GRAFTING", METHODS: A COMPANION TO METHODS IN ENZYMOLOGY, ACADEMIC PRESS INC., NEW YORK, NY, US, vol. 8, 1995, pages 83 - 93, XP002943667, ISSN: 1046-2023 *
MOLLER P ET AL: "CD74", JOURNAL OF BIOLOGICAL REGULATORS AND HOMEOSTATIC AGENTS 2000 ITALY, vol. 14, no. 4, 2000, pages 299 - 301, XP009018091, ISSN: 0393-974X *
OCHAKOVSKAYA R ET AL: "Therapy of disseminated B-cell lymphoma xenografts in severe combined immunodeficient mice with an anti-CD74 antibody conjugated with Indium, Gallium, or Yttrium", CLINICAL CANCER RESEARCH 2001 UNITED STATES, vol. 7, no. 6, 2001, pages 1505 - 1510, XP002255675, ISSN: 1078-0432 *
QU Z ET AL: "INTERNALIZATION AND CYTOTOXIC EFFECTS OF A HUMANIZED ANTI-CD74 ANTIBODY, LL1", PROCEEDINGS OF THE ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, NEW YORK, NY, US, vol. 43, March 2002 (2002-03-01), pages 255, XP001153818, ISSN: 0197-016X *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8906378B2 (en) 2005-04-06 2014-12-09 Ibc Pharmaceuticals, Inc. Combination therapy with anti-CD74 antibodies provides enhanced toxicity to malignancies, autoimmune disease and other diseases
US10981987B2 (en) 2007-07-16 2021-04-20 Genentech, Inc. Humanized anti-CD79b antibodies and immunoconjugates and methods of use
US11866496B2 (en) 2007-07-16 2024-01-09 Genentech, Inc. Humanized anti-CD79B antibodies and immunoconjugates and methods of use
US11000510B2 (en) 2014-09-23 2021-05-11 Genentech, Inc. Methods of using anti-CD79b immunoconjugates

Also Published As

Publication number Publication date
IL163851A (en) 2010-11-30
CN102174108A (en) 2011-09-07
JP5335651B2 (en) 2013-11-06
ES2350477T5 (en) 2020-05-06
US20110244546A1 (en) 2011-10-06
AU2003215732B2 (en) 2009-12-17
AU2009243494B2 (en) 2012-05-24
IL163851A0 (en) 2005-12-18
DK1483294T3 (en) 2010-11-08
EP1483294B2 (en) 2019-10-30
EP1483294A2 (en) 2004-12-08
US20100284906A1 (en) 2010-11-11
US20100266497A1 (en) 2010-10-21
US20110195023A1 (en) 2011-08-11
AU2009243494A1 (en) 2009-12-24
EP1483294B1 (en) 2010-08-11
US20100015048A1 (en) 2010-01-21
US20080138333A1 (en) 2008-06-12
CA2478012C (en) 2012-06-19
AU2003215732A1 (en) 2003-09-16
CN1649902B (en) 2011-04-13
EP2308898B1 (en) 2016-06-08
CN1649902A (en) 2005-08-03
US20040115193A1 (en) 2004-06-17
JP2006502699A (en) 2006-01-26
EP2865688A1 (en) 2015-04-29
JP2010088439A (en) 2010-04-22
ATE477276T1 (en) 2010-08-15
HK1071576A1 (en) 2005-07-22
EP2308898A1 (en) 2011-04-13
US7931903B2 (en) 2011-04-26
US7919087B2 (en) 2011-04-05
US7312318B2 (en) 2007-12-25
US7772373B2 (en) 2010-08-10
JP4472351B2 (en) 2010-06-02
US20080166342A1 (en) 2008-07-10
CN102174108B (en) 2016-06-29
CA2478012A1 (en) 2003-09-12
ES2350477T3 (en) 2011-01-24
WO2003074567A2 (en) 2003-09-12
DE60333732D1 (en) 2010-09-23
KR20040089695A (en) 2004-10-21
KR101017732B1 (en) 2011-02-28

Similar Documents

Publication Publication Date Title
IL163851A (en) Internalizing anti-cd74 antibodies and methods of use
HUS2200044I1 (en) Humanized anti-CD19 antibodies and their use in tumors, transplants and autoimmune diseases
WO2005012493A3 (en) Anti-cd19 antibodies
WO2003068821A3 (en) Anti-cd20 antibodies and fusion proteins thereof and methods of use
EP1485130A4 (en) REAGENTS AND TREATMENT PROCEDURES FOR AUTOIMMUNE DISEASES
PH12016500658B1 (en) Human anti-alpha-synuclein autoantibodies
TW200714711A (en) Anti-cd-20 monoclonal antibody
NZ594466A (en) Human monoclonal antibodies to protein tyrosine kinase 7 (PTK7) and methods for using anti-PTK7 antibodies
TN2010000616A1 (en) Human cytomegalovirus neutralising antibodies and use thereof
WO2006099141A3 (en) Anti-mesothelin antibodies
WO2008112003A3 (en) Targeted binding agents directed to pdgfr-alpha and uses thereof
WO2007092939A3 (en) Antigenic gm-csf peptides and antibodies to gm-csf
WO2006002438A3 (en) Human monoclonal antibodies to fc gamma receptor i (cd64)
MX2010006181A (en) Anti-human il-21 monoclonal antibodies.
WO2021203030A3 (en) Methods of use of anti-trem2 antibodies
WO2007126805A3 (en) Cancer immunotherapy compositions and methods of use
WO2004035742A3 (en) Sets of digital antibodies directed against short epitopes, and methods using same
WO2005028498A3 (en) Kid3 and kid3 antibodies that bind thereto
ZA202205383B (en) Novel anti-nogo-a antibodies
WO2009023055A3 (en) Blockade of the inhibitory qa-1-cd94/nkg2a pathway for treatment of autoimmune disease
MX2021008453A (en) Formulations of antibodies that bind human cd137 and uses thereof.
WO2004031354A3 (en) Human sarcoma-associated antigens
WO2006120473A3 (en) Mhc class i and ii peptide antigens derived from tumour antigen 5t4
MX2022013176A (en) Anti-cd19 antibodies and uses thereof.
MX360580B (en) Human anti-alpha-synuclein autoantibodies.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 163851

Country of ref document: IL

Ref document number: 2478012

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2003573032

Country of ref document: JP

Ref document number: 1020047013665

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2003215732

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2004129310

Country of ref document: RU

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2003743421

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1020047013665

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 20038098636

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2003743421

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 205985

Country of ref document: IL